Table 1 Demographic and baseline disease characteristics of patients with RA who received adalimumab at any time during the blinded period or open label extension of the ARMADA study (n = 262).
| Characteristic | Value | Range |
|---|---|---|
| Age (years) | 55 (11.8) | 27–83 |
| Female (%) | 76 | |
| Disease duration (years) | 12.4 (9.5) | 0.33–56.9 |
| Tender joint count (0–68 joints) | 28.4 (14.2) | 9–65 |
| Swollen joint count (0–68 joints) | 17.2 (8.6) | 2–43 |
| Patient's global assessment of pain (0–100 mm VAS)* | 52.6 (23) | 0–99 |
| Patient's global assessment of disease activity, (0–100 mm VAS)* | 55.6 (23.5) | 0–99 |
| Physician's global assessment of disease activity (0–100 mm VAS)* | 58.6 (18.2) | 2–95 |
| HAQ disability index, (0–3 scale)† | 1.55 (0.62) | 0.1–2.7 |
| DAS28‡ | 5.8 (1.0) | 2.9–8.1 |
| C reactive protein (mg/l) (normal <8) | 26 (26) | 0.5–173 |
| Rheumatoid factor (% positive) | 81.3 | |
| Number of previous DMARDs (mean) | 3 | 1–8 |
Values are mean (SD) unless stated otherwise.
*The visual analogue scale (VAS) for pain ranges from 0 = no pain to 100 = severe pain; VAS for disease activity ranges from 0 = no disease activity to 100 = extreme disease activity; †the Health Assessment Questionnaire (HAQ) scale ranges from 0 = no difficulty to 3 = unable to perform activity; ‡DAS28 is based on a 28 joint assessment for pain or swelling using the CRP based formula (www.das‐score.nl/www.das‐score.nl/index.html, accessed 9 December 2005).